ArticleJournal of arrhythmia2025
The efficacy and safety of intrinsic antitachycardia pacing.
Article in Journal of arrhythmia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The efficacy and safety of intrinsic antitachycardia pacing.Journal of arrhythmia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical outcomes of a novel antitachycardia pacing (ATP) algorithm-intrinsic ATP (iATP)-compared to conventional ATP (cATP) have yet to be fully elucidated. Methods: This retrospective study analyzed 128 patients and 1962 ventricular tachycardia (VT) episodes treated with the iATP or the cATP at Kokura Memorial Hospital. Patients were categorized into two groups: the iATP group (23 patients, 182 episodes) and the cATP group (105 patients, 1780 episodes). We evaluated ATP success rates and baseline patient characteristics on a per-patient basis. Additionally, we extracted VT that were not terminated by a single ATP and compared ATP success rates using propensity score matching. Results: Per patient; The iATP group exhibited significantly lower creatinine levels (1.18 ± 0.40 mg/dL vs. 1.82 ± 1.61 mg/dL, Conclusions: The efficacy and safety of the iATP for VT that was not terminated by the first sequence of ATP was demonstrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.